| Literature DB >> 30046740 |
Karel Maelegheer1, Katrien M J Devreese1.
Abstract
BACKGROUND: Pre-analytical factors, like freeze-thaw cycles (FTC), can potentially affect results and clinical interpretation. According to the SSC-ISTH recommendations for antiphospholipid antibodies (aPL) testing, additional FTC should be avoided to maintain the best performance. Patient samples are often analyzed in batch and having one frozen sample aliquot for all aPL tests, that may hamper daily routine work-out. To use them for study or method validation purpose, sample storage in bio banks is often done in one aliquot also triggering the need for several FTC to be able to use them in different scientific projects. Taking into account the limited scientific literature, the strict guidelines and the potential benefits of repeated FTC we evaluated this pre-analytical factor.Entities:
Keywords: antibodies; anticardiolipin; antiphospholipid antibodies; beta 2‐Glycoprotein I; diagnostic tests; protein stability; routine
Year: 2018 PMID: 30046740 PMCID: PMC6055575 DOI: 10.1002/rth2.12071
Source DB: PubMed Journal: Res Pract Thromb Haemost ISSN: 2475-0379
Routine results for all selected patient samples (n = 42) stored in the routine archive
| Negative | Around Cut off | Positive | Strong positive | |||||
|---|---|---|---|---|---|---|---|---|
| Range (U/ml) | # samples | Range (U/mL) | # samples | Range (U/ml) | # samples | Range (U/mL) | # samples | |
| aCL IgG | 3‐12 | 8 | 21‐34 | 6 | 53‐54 | 3 | 103‐480 | 10 |
| aCL IgM | 2‐18 | 7 | 22‐27 | 4 | 52‐70 | 7 | 104‐2330 | 6 |
| aβ2GPI IgM | 3‐9 | 7 | 21‐48 | 8 | 54‐88 | 3 | 107‐2705 | 6 |
| aβ2GPI IgG | 11‐18 | 9 | 23‐97 | 12 | 119‐186 | 4 | 213‐3153 | 12 |
aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.
Figure 1Timelaps studydesign *Thawing (37°C water bath 5 minutes); **Start analysis (every day in same order); ***Freezing of all samples at −20°C
Overview of Mann‐Withney test results between the first and following freeze thaw cycle
| Samples | FTC1 med(IQR) | FTC2 med (IQR) |
| FTC3 med (IQR) |
| FTC4 med (IQR) |
| FTC5 med (IQR) |
| |
|---|---|---|---|---|---|---|---|---|---|---|
| aCL IgG | 26 | 30(8‐93) | 32 (13‐263) | .8692 | 33(13‐274) | .7418 | 35(147‐237) | .7349 | 34(13‐276) | .7143 |
| aCL IgM | 24 | 55(13‐87) | 57(11‐88) | .8528 | 58(11‐90) | .765 | 59(11‐86) | .7259 | 57(8‐76) | .8481 |
| aβ2GPI IgM | 25 | 31(8‐93) | 28(9‐98) | .8234 | 31(8‐99) | .6908 | 29(9‐102) | .7784 | 31(8‐81) | .7949 |
| aβ2GPI IgG | 37 | 74(22‐676) | 73(18‐724) | .9354 | 79(15‐694) | .8642 | 74(11‐748) | .9058 | 74(13‐723) | .9551 |
aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.
Figure 2The CCC calculated between first and fifth FTC are graphically shown. Values above 200 U/mL are disregarded in the graph (for visual purposes), but were included in the concordance correlation coefficient calculation and showed no significant difference with values below 200 IU/ml aCL, anticardiolipin; aβ2GPI, anti‐beta‐2 glycoprotein 1; CCC, concordance correlation coefficient; FTC, freeze‐thaw cycle